Insights

Roth Capital Reaffirms EnteroMedics at Buy; Positive Bias Heading Into The FDA Panel

In a research note issued today, Roth Capital reiterated coverage with a “Buy” rating on EnteroMedics Inc. (ETRM), and a price target of $3.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts